ViaDerma, Inc. Announces Plan to Target Licensed Dispensaries in California after State Legalizes Recreational Marijuana & Seeks Reimbursement from Insurance Companies for its FDA Registered Topical Antibiotic Products

LOS ANGELES, CA–(Marketwired – January 23, 2018) – ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Company is working with a medical insurance consultant to get VitaStemtm , its FDA registered topical antibiotic ointment, approved for reimbursement by Health Insurance Companies. The medical insurance consultant successfully generated $70M annually for their previous product, an OTC pre-natal vitamin approved for reimbursement by insurance companies. It’s marketing, sales and distribution partner, Biogenx, Inc. has been selling the product, under the name of VitaStemtm, which now retails for $79 and can be purchased online at ViaDerma has streamlined the manufacturing process and expects to begin its third production run of the product. The Company also expects to increase production each month as interest in the product continues to grow.

The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma’s Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.

The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for “Aqueous Topical Applications” for human and veterinarian uses. The Company would combine its proprietary solutions with CBD’s and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) “Intellectual Property Portfolio” in 2018.

“We are extremely excited over our recent progress and are looking forward to having a breakout year in 2018,” stated Dr. Christopher Otiko, President of ViaDerma. “The State of California’s recent legalization of recreational cannabis has opened up many opportunities for us that we plan to take advantage of. We are also at a point where we are now manufacturing several of our new products and have begun to deliver high-quality pharmaceuticals to our distributors. We expect to continue expansion of our production each month as the demand for our products continues to grow throughout several key countries.”

About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s products use an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD’s and THC with the delivery system was filed in 2017. The use of CBD’s is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Crohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit:

Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.

Contact information:
Investor Relations
Email: [email protected]
Phone: 310-734-6111